ClinicalTrials.gg
CompletedNCT02264574Updated Sep 21, 2020Results posted

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

A Phase 3 interventional study of Ibrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia and Small-Cell Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 71 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-21.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
229
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
13th of 83
229 · median 44
Started
2014
with 7 others
Phase 3
14 of 83
none open now
Registered
26th of 83
by date
Lead sponsor
10 of 83
Pharmacyclics LLC.

Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 13th largest by enrollment, is one of 8 that started in 2014, is one of 14 in phase 3, and was the 26th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of ibrutinib in combination with obinutuzumab compared to chlorambucil in combination with obinutuzumab based on the Independent Review Committee (IRC) assessment of progression free survival (PFS). Efficacy will be evaluated according to 2008 International Workshop for Chronic Lymphocytic Leukemia (IWCLL) criteria with the modification for treatment-related lymphocytosis, in subjects with treatment-naive CLL or SLL.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small-Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Disease Related:

  1. Diagnosis of CLL/SLL that meets IWCLL diagnostic criteria.
  2. Age 65 yrs and older OR if less than 65 years, must have at least one of the following criteria:

    • Cumulative Illness Rating Score (CIRS) >6
    • estimated \<70 mL/min using Cockcroft-Gault equation.
    • Del 17p by fluorescence in situ hybridization (FISH) or TP53 mutation by polymerase chain reaction (PCR) or Next Generation Sequencing
  3. Active disease meeting at least 1 of the following IWCLL criteria for requiring treatment:

    • Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and thrombocytopenia
    • Massive, progressive, or symptomatic splenomegaly
    • Massive nodes (at least 10 cm longest diameter), or progressive or symptomatic lymphadenopathy.
    • Progressive lymphocytosis with an increase of more than 50 percent over a 2-month period or a lymphocyte doubling time (LDT) of \<6 months. LDT may be obtained by linear regression extrapolation of absolute lymphocyte counts obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In patients with initial blood lymphocyte counts of \<30,000/µL, LDT should not be used as a single parameter to define indication for treatment. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (eg, infections) should be excluded.
    • hemolytic anemia and/or immune thrombocytopenia that is poorly responsive to or other standard therapy.
    • Autoimmune hemolytic anemia is defined by at least one marker of hemolysis (indirect above the (ULN) not due to liver disease, increased lactate dehydrogenase (above ULN) without alternative etiology, or increased absolute reticulocytosis (above ULN) or bone marrow erythropoiesis in the absence of bleeding AND at least one marker direct or indirect autoimmune mechanism (positive direct antiglobulin for immunoglobulin G [IgG] or C3d, cold agglutinins).
    • Immune thrombocytopenia is defined by ≤100,000/µL and increased megakaryocytes on the bone marrow exam.
    • Constitutional symptoms, defined as one or more of the following disease-related symptoms or signs, documented in the patient's record prior to randomization:
    • unintentional weight loss >10 percent within 6 months prior to screening.
    • significant fatigue (inability to work or perform usual activities).
    • fevers >100.5°F or 38.0°C for 2 or more weeks prior to screening without evidence of infection.
    • night sweats for more than 1 month prior to screening without evidence of infection.
  4. Measurable nodal disease by computed tomography (CT), defined as at least 1 lymph node >1.5 cm in the longest diameter in a site that has not been previously irradiated. An irradiated lesion may be assessed for only if there has been documented progression in that lesion since radiotherapy has ended.

    Laboratory

  5. Adequate hematologic function independent of transfusion and growth factor support for at least 7 days prior to screening and randomization.
  6. Adequate hepatic and renal function
  7. Men and women ≥ 18 years of age.
  8. (ECOG) performance status of 0 to 2.

Exclusion criteria

Exclusion Criteria:

  1. Any prior treatment of CLL or SLL
  2. Evidence of central nervous system (CNS) involvement with primary disease of CLL/SLL
  3. History of other , except:

    • Malignancy treated with curative intent and with no known active disease present for ≥3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician.
  4. Uncontrolled hemolytic anemia or idiopathic thrombocytopenic purpura
  5. Known or suspected history of Richter's transformation.
  6. Concurrent administration of >20mg/day of prednisone within 7 days of randomization unless indicated for prophylaxis or management of allergic reactions (eg, contrast)
  7. Known to one or more study drugs
  8. Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.
  9. Any uncontrolled active systemic infection or an infection requiring systemic treatment that was completed ≤ 7 days before randomization.
  10. Known bleeding disorders or hemophilia.
  11. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
  12. Known history of (HIV) or active with virus (HBV) or virus (HCV).
  13. Major surgery within 4 weeks of randomization.
  14. Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.
  15. Currently active, cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization.
  16. Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction.
  17. Concomitant use of warfarin or other vitamin K antagonists.
  18. Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor.
  19. Lactating or pregnant
  20. Unwilling or unable to participate in all required study evaluations and procedures.
  21. Unable to understand the purpose and risks of the study and to provide a signed and dated form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
229 participants (actual)

Study arms

  • Experimental
    IBR + OB

    Ibrutinib (IBR) given orally at a dose of 420 mg/day until progressive disease or unacceptable toxicity. Intravenous obinutuzumab (OB) given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until progressive disease or unacceptable toxicity.

    Drug: Ibrutinib · Drug: Obinutuzumab

  • Experimental
    CLB + OB

    Chlorambucil (CLB) given orally at a dose of 0.5 mg/kg body weight up to a total of 6 cycles on Days 1 and 15 of each cycle or until disease progression or unacceptable toxicity. Intravenous obinutuzumab given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until disease progression or unacceptable toxicity.

    Drug: Obinutuzumab · Drug: Chlorambucil

Interventions

  • Ibrutinib will be supplied as 140 mg hard gelatin capsules for oral (PO) administration.

  • Obinutuzumab will be supplied as 1000 mg/40 mL solution in a single-use vial for intravenous (IV) administration

  • Chlorambucil will be supplied as 2 mg film-coated tablets for oral (PO) administration

06

What researchers measure

Primary outcomes

  1. Primary Analysis: Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 30

    PFS was defined as time from the date randomization to the date of first IRC-confirmed disease progression (PD) or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of disease progression was not considered progressive disease. The primary analysis was performed after observing 94 PFS events as pre-specified in the study protocol. As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 30 months (that is, the estimated percentage of participants with progression-free survival at Month 30) are presented.

    Time frame: Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).

  2. Final Analysis: PFS Based on Investigator Assessment - Kaplan Meier Landmark Estimates at Month 48

    PFS was defined as time from the date randomization to the date of first investigator-confirmed PD or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of disease progression was not considered progressive disease. As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 48 months (that is, the estimated percentage of participants with progression-free survival at Month 48) are presented.

    Time frame: Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]).

Secondary outcomes

  1. Primary Analysis: PFS in High-Risk Sub-Population (del17p/TP53 Mutation/Del 11q) Based on IRC Assessment - Kaplan Meier Landmark Estimates at Month 30

    PFS was analyzed within the high-risk sub-population of participants with del17p or TP53 mutation or del 11q at baseline per central lab results. PFS was defined as time from the date randomization to the date of first IRC-confirmed PD or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the IWCLL 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of PD was not considered progressive disease. As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 30 months (that is, the estimated percentage of participants with progression-free survival at Month 30) are presented.

    Time frame: Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).

  2. Primary Analysis: Rate of Sustained Hemoglobin Improvement

    Percentage of participants with sustained hemoglobin improvement, defined as hemoglobin increase ≥ 2 g/dL over baseline continuously for ≥ 56 days without blood transfusions or growth factors.

    Time frame: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).

  3. Primary Analysis: Rate of Minimal Residual Disease (MRD)-Negative Response

    Percentage of participants who achieved MRD-negative response, defined as \< 1 CLL cell per 10,000 leukocytes as assessed by flow cytometry of a bone marrow aspirate per central laboratory. MRD samples were collected before initiation of subsequent antineoplastic treatment and MRD status was reported by central lab within 5 days after collection date. Participants with missing MRD data were considered non-responders.

    Time frame: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).

  4. Primary Analysis: Overall Response Rate (ORR) Based on IRC Assessment

    ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), CR with incomplete blood count recovery (CRi), nodular partial response (nPR), or partial response (PR) per IRC assessment at or prior to initiation of subsequent antineoplastic therapy. Assessment of response included physical examination, radiographic imaging, and evaluation of blood and marrow (if applicable), evaluated in accordance with the IWCLL 2008 criteria (Halleck et al). CR, CRi, nPR, and PR required confirmation with 2 consecutive assessments that were at least 56 days apart and no use of blood supportive product and/or growth factor during this period. Kaplan-Meier estimate.

    Time frame: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).

  5. Primary Analysis: Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 30

    OS, defined as the time from the date of randomization to the date of death from any cause. All deaths observed as the time of the analysis were considered as events. For participants who were not known to have died at the time of the analysis, OS data were censored at the date last known alive. As the median OS was not reached in either treatment arm at the time of the analysis, Kaplan Meier landmark estimates of the OS rate (that is, the estimated percentage of participants still surviving at Month 30 \[primary analysis\]) are presented.

    Time frame: Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).

  6. Primary Analysis: Rate of Grade ≥ 3 or Serious Infusion-Related Reaction (IRR) Adverse Events

    Percentage of participants experiencing grade ≥ 3 (severe or life threatening) or serious IRR adverse events that started on the day of an obinutuzumab infusion and were assessed as related or possibly related to obinutuzumab. Categories included those events with the Medical Dictionary for Regulatory Activities (MedDRA) dictionary preferred term of IRR and those events which are among the customized standardized MedDRA query (SMQ) for IRR.

    Time frame: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).

  7. Primary Analysis: Rate of Sustained Platelet Improvement

    Percentage of participants with platelet counts increase ≥ 50% over baseline continuously for ≥ 56 days without blood transfusion or growth factors.

    Time frame: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).

  8. Primary Analysis: Rate of Clinically Meaningful Improvement in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire EuroQol Five-Dimension (EQ-5D-5L)

    Percentage of participants with EQ-5D-5L utility score increase ≥ 0.08 points over baseline at or prior to initiation of subsequent antineoplastic therapy. The EQ-5D-5L is a standardized non-disease specific instrument for describing and valuing health-related quality of life, comprising 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. A unique EQ-5D-5L health state is defined by combining the numeric level scores for each of the 5 dimensions and the total score is normalized from -0.594 to 1.000, with higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement. Participants with missing EQ-5D-5L data were considered not achieving clinically meaningful improvement.

    Time frame: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).

  9. Final Analysis: PFS in High-Risk Population (del17p/TP53 Mutation/Del 11q/Unmutated Immunoglobulin Heavy Chain Variable Region [IGHV]) Based on Investigator Assessment - Kaplan Meier Landmark Estimates at Month 48

    PFS was analyzed within the high-risk population of participants with del17p or TP53 mutation or del 11q or IGHV unmutated at baseline per central lab results. PFS was defined as time from the date randomization to the date of first investigator-confirmed PD or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the IWCLL 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of PD was not considered progressive disease. As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 48 months (that is, the estimated percentage of participants with progression-free survival at Month 48) are presented.

    Time frame: Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]).

  10. Final Analysis: Rate of Sustained Hemoglobin Improvement

    Percentage of participants with sustained hemoglobin improvement, defined as hemoglobin increase ≥ 2 g/dL over baseline continuously for ≥ 56 days without blood transfusions or growth factors.

    Time frame: Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).

  11. Final Analysis: Rate of Minimal Residual Disease (MRD)-Negative Response

    Percentage of participants who achieved MRD-negative response, defined as \< 1 CLL cell per 10,000 leukocytes as assessed by flow cytometry of a bone marrow aspirate per central laboratory. MRD samples were collected before initiation of subsequent antineoplastic treatment and MRD status was reported by central lab within 5 days after collection date. Participants with missing MRD data were considered non-responders.

    Time frame: Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).

  12. Final Analysis: ORR Based on Investigator Assessment

    ORR, defined as the percentage of participants achieving a best overall response of protocol-specified CR, CRi, nPR or PR per investigator assessment at or prior to initiation of subsequent antineoplastic therapy. Assessment of response included physical examination, radiographic imaging, and evaluation of blood and marrow (if applicable), evaluated in accordance with the IWCLL 2008 criteria (Halleck et al). CR, CRi, nPR, and PR required confirmation with 2 consecutive assessments that were at least 56 days apart and no use of blood supportive product and/or growth factor during this period. Kaplan-Meier estimate.

    Time frame: Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).

  13. Final Analysis: Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 48

    OS, defined as the time from the date of randomization to the date of death from any cause. All deaths observed as the time of the analysis were considered as events. For participants who were not known to have died at the time of the analysis, OS data were censored at the date last known alive. As the median OS was not reached in either treatment arm at the time of the analysis, Kaplan Meier point estimates of the OS rate (that is, the estimated percentage of participants still surviving at Month 48 \[final analysis\]) are presented.

    Time frame: Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]).

  14. Final Analysis: Rate of Sustained Platelet Improvement

    Percentage of participants with platelet counts increase ≥ 50% over baseline continuously for ≥ 56 days without blood transfusion or growth factors.

    Time frame: Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).

07

Results

Posted Apr 16, 2019

Participant flow

This study was conducted in 71 sites: 8 in the US, 36 in the EU, and 27 sites in 6 additional countries (Canada, Australia, New Zealand, Russia, Israel, Turkey). The first participant consented 06 October 2014. The last visit of the last participant was 03 September 2019, with a final database lock of 17 October 2019.

Participant flow — Overall Study
MilestoneIBR+OBCLB+OB
Started113116
Completed8486
Not completed2930
Withdrew: Death2121
Withdrew: Withdrawal by subject86
Withdrew: Other, not specified03

Outcome measures

PrimaryPrimary Analysis: Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 30

PFS was defined as time from the date randomization to the date of first IRC-confirmed disease progression (PD) or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of disease progression was not considered progressive disease. The primary analysis was performed after observing 94 PFS events as pre-specified in the study protocol. As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 30 months (that is, the estimated percentage of participants with progression-free survival at Month 30) are presented.

Time frame:
Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).
Reported as:
Number · percentage of participants
Primary Analysis: Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 30
percentage of participantsIBR+OBCLB+OB
Primary Analysis: Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 3078.5 (69.5 to 85.2)31.1 (22.5 to 40.0)
Statistical analysis
  • IBR+OB vs CLB+OB · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.231 · 95% CI 0.145 to 0.367The hazard ratio and its 95% confidence interval were estimated using a Cox regression model with treatment as the only covariate.
SecondaryPrimary Analysis: PFS in High-Risk Sub-Population (del17p/TP53 Mutation/Del 11q) Based on IRC Assessment - Kaplan Meier Landmark Estimates at Month 30

PFS was analyzed within the high-risk sub-population of participants with del17p or TP53 mutation or del 11q at baseline per central lab results. PFS was defined as time from the date randomization to the date of first IRC-confirmed PD or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the IWCLL 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of PD was not considered progressive disease. As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 30 months (that is, the estimated percentage of participants with progression-free survival at Month 30) are presented.

Time frame:
Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).
Reported as:
Number · percentage of participants
Primary Analysis: PFS in High-Risk Sub-Population (del17p/TP53 Mutation/Del 11q) Based on IRC Assessment - Kaplan Meier Landmark Estimates at Month 30
percentage of participantsIBR+OBCLB+OB
Primary Analysis: PFS in High-Risk Sub-Population (del17p/TP53 Mutation/Del 11q) Based on IRC Assessment - Kaplan Meier Landmark Estimates at Month 3082.4 (62.7 to 92.3)14.1 (5.3 to 26.9)
Statistical analysis
  • IBR+OB vs CLB+OB · Log Rank · p = < 0.0001 · Hazard ratio (hr): 0.119 · 95% CI 0.046 to 0.307The hazard ratio and its 95% confidence interval were estimated using a Cox regression model with treatment as the only covariate.
SecondaryPrimary Analysis: Rate of Sustained Hemoglobin Improvement

Percentage of participants with sustained hemoglobin improvement, defined as hemoglobin increase ≥ 2 g/dL over baseline continuously for ≥ 56 days without blood transfusions or growth factors.

Time frame:
Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Reported as:
Number · percentage of participants
Primary Analysis: Rate of Sustained Hemoglobin Improvement
percentage of participantsIBR+OBCLB+OB
Primary Analysis: Rate of Sustained Hemoglobin Improvement39.844.0
Statistical analysis
  • IBR+OB vs CLB+OB · Chi-squared · p = 0.5253
SecondaryPrimary Analysis: Rate of Minimal Residual Disease (MRD)-Negative Response

Percentage of participants who achieved MRD-negative response, defined as \< 1 CLL cell per 10,000 leukocytes as assessed by flow cytometry of a bone marrow aspirate per central laboratory. MRD samples were collected before initiation of subsequent antineoplastic treatment and MRD status was reported by central lab within 5 days after collection date. Participants with missing MRD data were considered non-responders.

Time frame:
Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Reported as:
Number · percentage of participants
Primary Analysis: Rate of Minimal Residual Disease (MRD)-Negative Response
percentage of participantsIBR+OBCLB+OB
Primary Analysis: Rate of Minimal Residual Disease (MRD)-Negative Response20.417.2
Statistical analysis
  • IBR+OB vs CLB+OB · Chi-squared · p = 0.5465
SecondaryPrimary Analysis: Overall Response Rate (ORR) Based on IRC Assessment

ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), CR with incomplete blood count recovery (CRi), nodular partial response (nPR), or partial response (PR) per IRC assessment at or prior to initiation of subsequent antineoplastic therapy. Assessment of response included physical examination, radiographic imaging, and evaluation of blood and marrow (if applicable), evaluated in accordance with the IWCLL 2008 criteria (Halleck et al). CR, CRi, nPR, and PR required confirmation with 2 consecutive assessments that were at least 56 days apart and no use of blood supportive product and/or growth factor during this period. Kaplan-Meier estimate.

Time frame:
Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Reported as:
Number · percentage of participants
Primary Analysis: Overall Response Rate (ORR) Based on IRC Assessment
percentage of participantsIBR+OBCLB+OB
Primary Analysis: Overall Response Rate (ORR) Based on IRC Assessment88.573.3
Statistical analysis
  • IBR+OB vs CLB+OB · Chi-squared · p = 0.0035 · Rate ratio: 1.208 · 95% CI 1.062 to 1.373
SecondaryPrimary Analysis: Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 30

OS, defined as the time from the date of randomization to the date of death from any cause. All deaths observed as the time of the analysis were considered as events. For participants who were not known to have died at the time of the analysis, OS data were censored at the date last known alive. As the median OS was not reached in either treatment arm at the time of the analysis, Kaplan Meier landmark estimates of the OS rate (that is, the estimated percentage of participants still surviving at Month 30 \[primary analysis\]) are presented.

Time frame:
Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).
Reported as:
Number · percentage of participants
Primary Analysis: Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 30
percentage of participantsIBR+OBCLB+OB
Primary Analysis: Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 3085.5 (77.4 to 90.9)84.9 (76.8 to 90.4)
Statistical analysis
  • IBR+OB vs CLB+OB · Log Rank · p = 0.8057 · Hazard ratio (hr): 0.921 · 95% CI 0.479 to 1.772The hazard ratio and its 95% confidence interval were estimated using a Cox regression model with treatment as the only covariate.
SecondaryPrimary Analysis: Rate of Grade ≥ 3 or Serious Infusion-Related Reaction (IRR) Adverse Events

Percentage of participants experiencing grade ≥ 3 (severe or life threatening) or serious IRR adverse events that started on the day of an obinutuzumab infusion and were assessed as related or possibly related to obinutuzumab. Categories included those events with the Medical Dictionary for Regulatory Activities (MedDRA) dictionary preferred term of IRR and those events which are among the customized standardized MedDRA query (SMQ) for IRR.

Time frame:
Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Reported as:
Number · percentage of participants
Primary Analysis: Rate of Grade ≥ 3 or Serious Infusion-Related Reaction (IRR) Adverse Events
percentage of participantsIBR+OBCLB+OB
IRR (Preferred Term)2.78.6
By Customized SMQ4.49.5
Statistical analysis
  • IBR+OB vs CLB+OB · Fisher Exact · p = 0.0835
  • IBR+OB vs CLB+OB · Fisher Exact · p = 0.1944
SecondaryPrimary Analysis: Rate of Sustained Platelet Improvement

Percentage of participants with platelet counts increase ≥ 50% over baseline continuously for ≥ 56 days without blood transfusion or growth factors.

Time frame:
Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Reported as:
Number · percentage of participants
Primary Analysis: Rate of Sustained Platelet Improvement
percentage of participantsIBR+OBCLB+OB
Primary Analysis: Rate of Sustained Platelet Improvement29.213.8
Statistical analysis
  • IBR+OB vs CLB+OB · Chi-squared · p = 0.0045
SecondaryPrimary Analysis: Rate of Clinically Meaningful Improvement in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire EuroQol Five-Dimension (EQ-5D-5L)

Percentage of participants with EQ-5D-5L utility score increase ≥ 0.08 points over baseline at or prior to initiation of subsequent antineoplastic therapy. The EQ-5D-5L is a standardized non-disease specific instrument for describing and valuing health-related quality of life, comprising 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. A unique EQ-5D-5L health state is defined by combining the numeric level scores for each of the 5 dimensions and the total score is normalized from -0.594 to 1.000, with higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement. Participants with missing EQ-5D-5L data were considered not achieving clinically meaningful improvement.

Time frame:
Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Reported as:
Number · percentage of participants
Primary Analysis: Rate of Clinically Meaningful Improvement in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire EuroQol Five-Dimension (EQ-5D-5L)
percentage of participantsIBR+OBCLB+OB
Primary Analysis: Rate of Clinically Meaningful Improvement in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire EuroQol Five-Dimension (EQ-5D-5L)54.956.0
Statistical analysis
  • IBR+OB vs CLB+OB · Chi-squared · p = 0.8590
SecondaryFinal Analysis: PFS in High-Risk Population (del17p/TP53 Mutation/Del 11q/Unmutated Immunoglobulin Heavy Chain Variable Region [IGHV]) Based on Investigator Assessment - Kaplan Meier Landmark Estimates at Month 48

PFS was analyzed within the high-risk population of participants with del17p or TP53 mutation or del 11q or IGHV unmutated at baseline per central lab results. PFS was defined as time from the date randomization to the date of first investigator-confirmed PD or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the IWCLL 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of PD was not considered progressive disease. As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 48 months (that is, the estimated percentage of participants with progression-free survival at Month 48) are presented.

Time frame:
Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]).
Reported as:
Number · percentage of participants
Final Analysis: PFS in High-Risk Population (del17p/TP53 Mutation/Del 11q/Unmutated Immunoglobulin Heavy Chain Variable Region [IGHV]) Based on Investigator Assessment - Kaplan Meier Landmark Estimates at Month 48
percentage of participantsIBR+OBCLB+OB
Final Analysis: PFS in High-Risk Population (del17p/TP53 Mutation/Del 11q/Unmutated Immunoglobulin Heavy Chain Variable Region [IGHV]) Based on Investigator Assessment - Kaplan Meier Landmark Estimates at Month 4870.3 (57.6 to 79.8)8.0 (2.3 to 18.6)
Statistical analysis
  • IBR+OB vs CLB+OB · Log Rank · p = < 0.0001 · Hazard ratio (hr): 0.169 · 95% CI 0.102 to 0.282The hazard ratio and its 95% confidence interval were estimated using a Cox regression model with treatment as the only covariate.
SecondaryFinal Analysis: Rate of Sustained Hemoglobin Improvement

Percentage of participants with sustained hemoglobin improvement, defined as hemoglobin increase ≥ 2 g/dL over baseline continuously for ≥ 56 days without blood transfusions or growth factors.

Time frame:
Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).
Reported as:
Number · percentage of participants
Final Analysis: Rate of Sustained Hemoglobin Improvement
percentage of participantsIBR+OBCLB+OB
Final Analysis: Rate of Sustained Hemoglobin Improvement44.244.0
Statistical analysis
  • IBR+OB vs CLB+OB · Chi-squared · p = 0.9657
SecondaryFinal Analysis: Rate of Minimal Residual Disease (MRD)-Negative Response

Percentage of participants who achieved MRD-negative response, defined as \< 1 CLL cell per 10,000 leukocytes as assessed by flow cytometry of a bone marrow aspirate per central laboratory. MRD samples were collected before initiation of subsequent antineoplastic treatment and MRD status was reported by central lab within 5 days after collection date. Participants with missing MRD data were considered non-responders.

Time frame:
Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).
Reported as:
Number · percentage of participants
Final Analysis: Rate of Minimal Residual Disease (MRD)-Negative Response
percentage of participantsIBR+OBCLB+OB
Final Analysis: Rate of Minimal Residual Disease (MRD)-Negative Response24.817.2
Statistical analysis
  • IBR+OB vs CLB+OB · Chi-squared · p = 0.1612
SecondaryFinal Analysis: ORR Based on Investigator Assessment

ORR, defined as the percentage of participants achieving a best overall response of protocol-specified CR, CRi, nPR or PR per investigator assessment at or prior to initiation of subsequent antineoplastic therapy. Assessment of response included physical examination, radiographic imaging, and evaluation of blood and marrow (if applicable), evaluated in accordance with the IWCLL 2008 criteria (Halleck et al). CR, CRi, nPR, and PR required confirmation with 2 consecutive assessments that were at least 56 days apart and no use of blood supportive product and/or growth factor during this period. Kaplan-Meier estimate.

Time frame:
Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).
Reported as:
Number · percentage of participants
Final Analysis: ORR Based on Investigator Assessment
percentage of participantsIBR+OBCLB+OB
Final Analysis: ORR Based on Investigator Assessment91.281.0
Statistical analysis
  • IBR+OB vs CLB+OB · Chi-squared · p = 0.0273 · Rate ratio: 1.125 · 95% CI 1.013 to 1.250
SecondaryFinal Analysis: Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 48

OS, defined as the time from the date of randomization to the date of death from any cause. All deaths observed as the time of the analysis were considered as events. For participants who were not known to have died at the time of the analysis, OS data were censored at the date last known alive. As the median OS was not reached in either treatment arm at the time of the analysis, Kaplan Meier point estimates of the OS rate (that is, the estimated percentage of participants still surviving at Month 48 \[final analysis\]) are presented.

Time frame:
Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]).
Reported as:
Number · percentage of participants
Final Analysis: Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 48
percentage of participantsIBR+OBCLB+OB
Final Analysis: Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 4880.5 (71.6 to 86.9)81.3 (72.8 to 87.4)
Statistical analysis
  • IBR+OB vs CLB+OB · Log Rank · p = 0.7934 · Hazard ratio (hr): 1.083 · 95% CI 0.595 to 1.973The hazard ratio and its 95% confidence interval were estimated using a Cox regression model with treatment as the only covariate.
SecondaryFinal Analysis: Rate of Sustained Platelet Improvement

Percentage of participants with platelet counts increase ≥ 50% over baseline continuously for ≥ 56 days without blood transfusion or growth factors.

Time frame:
Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).
Reported as:
Number · percentage of participants
Final Analysis: Rate of Sustained Platelet Improvement
percentage of participantsIBR+OBCLB+OB
Final Analysis: Rate of Sustained Platelet Improvement30.114.7
Statistical analysis
  • IBR+OB vs CLB+OB · Chi-squared · p = 0.0050
PrimaryFinal Analysis: PFS Based on Investigator Assessment - Kaplan Meier Landmark Estimates at Month 48

PFS was defined as time from the date randomization to the date of first investigator-confirmed PD or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of disease progression was not considered progressive disease. As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 48 months (that is, the estimated percentage of participants with progression-free survival at Month 48) are presented.

Time frame:
Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]).
Reported as:
Number · percentage of participants
Final Analysis: PFS Based on Investigator Assessment - Kaplan Meier Landmark Estimates at Month 48
percentage of participantsIBR+OBCLB+OB
Final Analysis: PFS Based on Investigator Assessment - Kaplan Meier Landmark Estimates at Month 4874.0 (64.3 to 81.4)22.0 (11.0 to 35.4)
Statistical analysis
  • IBR+OB vs CLB+OB · Log Rank · p = < 0.0001 · Hazard ratio (hr): 0.251 · 95% CI 0.162 to 0.389The hazard ratio and its 95% confidence interval were estimated using a Cox regression model with treatment as the only covariate.

Adverse events

Collected over From first dose of study drug up to 30 days after the last dose of study drug. Median treatment duration for the IBR+OB arm was 42.3 (IBR) and 4.6 (OB) months. Median treatment duration for the CLB+OB arm was 5.1 (CLB) and 4.6 (OB) months. Final analysis data (data cutoff date: 17 October 2019).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IBR+OB22/113 (19.5%)69/113 (61.1%)112/113 (99.1%)
CLB+OB21/115 (18.3%)41/115 (35.7%)111/115 (96.5%)
Most frequent serious events
Showing 10 of 146
Most frequent serious events
EventIBR+OBCLB+OB
PneumoniaInfections and infestations8/1135/115
Infusion related reactionInjury, poisoning and procedural complications2/1138/115
Febrile neutropeniaBlood and lymphatic system disorders5/1137/115
Atrial fibrillationCardiac disorders6/1130/115
Tumour lysis syndromeMetabolism and nutrition disorders0/1135/115
PyrexiaGeneral disorders4/1134/115
ThrombocytopeniaBlood and lymphatic system disorders3/1131/115
Acute coronary syndromeCardiac disorders3/1130/115
GastroenteritisInfections and infestations3/1131/115
Urinary tract infectionInfections and infestations3/1131/115
Most frequent other events
Showing 10 of 72
Most frequent other events
EventIBR+OBCLB+OB
NeutropeniaBlood and lymphatic system disorders50/11373/115
Infusion related reactionInjury, poisoning and procedural complications26/11361/115
ThrombocytopeniaBlood and lymphatic system disorders39/11329/115
DiarrheaGastrointestinal disorders39/11312/115
NauseaGastrointestinal disorders15/11334/115
CoughRespiratory, thoracic and mediastinal disorders33/11314/115
AnaemiaBlood and lymphatic system disorders19/11329/115
PyrexiaGeneral disorders19/11328/115
ArthralgiaMusculoskeletal and connective tissue disorders27/11312/115
FatigueGeneral disorders22/11319/115

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IBR+OBCLB+OBTotal
<=18 years000
Between 18 and 65 years222446
>=65 years9192183
Age, Continuous
Age, Continuous(years)IBR+OBCLB+OBTotal
Median70.0 (47 to 87)72.0 (40 to 86)71.0 (40 to 87)
Sex: Female, Male
Sex: Female, Male(Participants)IBR+OBCLB+OBTotal
Female463783
Male6779146
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IBR+OBCLB+OBTotal
Hispanic or Latino4610
Not Hispanic or Latino109110219
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IBR+OBCLB+OBTotal
American Indian or Alaska Native000
Asian123
Native Hawaiian or Other Pacific Islander112
Black or African American224
White109111220
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)IBR+OBCLB+OBTotal
United States131124
Czechia8614
United Kingdom224
Spain17926
Russia11920
New Zealand099
Canada358
Austria5611
Sweden8311
Turkey151328
Belgium224
Poland224
Italy131528
Israel51116
France358
Australia6814
08

Study locations

71 sites
  • Site Reference ID/Investigator# 0241
    La Jolla, California, United States
  • Site Reference ID/Investigator# 0844
    Fort Myers, Florida, United States
  • Site Reference ID/Investigator# 0763
    West Palm Beach, Florida, United States
  • Site Reference ID/Investigator# 071
    Louisville, Kentucky, United States
  • Site Reference ID/Investigator# 0712
    Las Vegas, Nevada, United States
  • Site Reference ID/Investigator# 0845
    Cincinnati, Ohio, United States
  • Site Reference ID/Investigator# 0868
    Chattanooga, Tennessee, United States
  • Site Reference ID/Investigator# 0123
    Nashville, Tennessee, United States
  • Site Reference ID/Investigator #0503
    Woolloongabba, Queensland, Australia
  • Site Reference ID/Investigator# 0650
    Adelaide, South Australia, Australia
  • Site Reference ID/Investigator# 0888
    Ballarat, Victoria, Australia
  • Site Reference ID/Investigator# 0193
    Box Hill, Victoria, Australia
  • Site Reference ID/Investigator# 0633
    Fitzroy, Victoria, Australia
  • Site Reference ID/Investigator# 0170
    Heidelberg, Victoria, Australia
  • Site Reference ID/Investigator# 0352
    Linz, Austria
  • Site Reference ID/Investigator# 0869
    Salzburg, Austria
  • Site Reference ID/Investigator# 0559
    Leuven, Belgium
  • Site Reference ID/Investigator# 0850
    Turnhout, Belgium
  • Site Reference ID/Investigator# 018
    Edmonton, Alberta, Canada
  • Site Reference ID/Investigator# 0564
    Hradec Kralove, Czechia
  • Site Reference ID/Investigator# 0854
    Praha 10, Czechia
  • Site Reference ID/Investigator# 0769
    Pessac cedex, Gironde, France
  • Site Reference ID/Investigator# 0520
    Nantes cedex 1, Loire Atlantique, France
  • Site Reference ID/Investigator# 0775
    Vandoeuvre les Nancy, Meurthe Et Moselle, France
  • Site Reference ID/Investigator# 0855
    Bayonne, Pyrenees Atlantiques, France
  • Site Reference ID/Investigator# 0573
    Haifa, Israel
  • Site Reference ID/Investigator# 0577
    Jerusalem, Israel
  • Site Reference ID/Investigator# 0579
    Jerusalem, Israel
  • Site Reference ID/Investigator# 0575
    Petach Tikva, Israel
  • Site Reference ID/Investigator# 0856
    Tel Aviv, Israel
  • Site Reference ID/Investigator# 0875
    Zerifin, Israel
  • Site Reference ID/Investigator# 0860
    Firenze, Italy
  • Site Reference ID/Investigator# 0523
    Milano, Italy
  • Site Reference ID/Investigator# 0581
    Milano, Italy
  • Site Reference ID/Investigator# 0584
    Milano, Italy
  • Site Reference ID/Investigator# 0524
    Modena, Italy
  • Site Reference ID/Investigator# 0582
    Novara, Italy
  • Site Reference ID/Investigator# 0732
    Roma, Italy
  • Site Reference ID/Investigator# 0859
    Siena, Italy
  • Site Reference ID/Investigator# 0663
    Auckland, New Zealand
  • Site Reference ID/Investigator# 662
    Auckland, New Zealand
  • Site Reference ID/Investigator# 0586
    Hamilton, New Zealand
  • Site Reference ID/Investigator# 0592
    Brzozow, Poland
  • Site Reference ID/Investigator# 0531
    Lodz, Poland
  • Site Reference ID/Investigator# 0708
    Nizhniy Novgorod, Russian Federation
  • Site Reference ID/Investigator# 0707
    Ryazan, Russian Federation
  • Site Reference ID/Investigator# 0881
    Saint-Petersburg, Russian Federation
  • Site Reference ID/Investigator# 710
    St. Petersburg, Russian Federation
  • Site Reference ID/Investigator# 304
    Yaroslavl, Russian Federation
  • Site Reference ID/Investigator# 0604
    L'Hospitalet de Llobregat, Madrid, Spain
  • Site Reference ID/Investigator# 0536
    Majadahonda, Madrid, Spain
  • Site Reference ID/Investigator# 0533
    Barcelona, Spain
  • Site Reference ID/Investigator# 0534
    Barcelona, Spain
  • Site Reference ID/Investigator# 0535
    Barcelona, Spain
  • Site Reference ID/Investigator# 0537
    Madrid, Spain
  • Site Reference ID/Investigator# 0864
    Madrid, Spain
  • Site Reference ID/Investigator# 0874
    Madrid, Spain
  • Site Reference ID/Investigator# 0790
    Salamanca, Spain
  • Site Reference ID/Investigator# 0870
    Borås, Sweden
  • Site Reference ID/Investigator# 0865
    Luleå, Sweden
  • Site Reference ID/Investigator# 0631
    Lund, Sweden
  • Site Reference ID/Investigator# 0632
    Stockholm, Sweden
  • Site Reference ID/Investigator# 0678
    Istanbul, Nisantasi, Turkey
  • Site Reference ID/Investigator# 0608
    Ankara, Turkey
  • Site Reference ID/Investigator# 606
    Ankara, Turkey
  • Site Reference ID/Investigator# 0889
    Denizli, Turkey
  • Site Reference ID/Investigator# 0601
    Izmir, Turkey
  • Site Reference ID/Investigator# 0866
    Samsun, Turkey
  • Site Reference ID/Investigator# 0867
    Harlow, Essex, United Kingdom
  • Site Reference ID/Investigator# 0365
    London, United Kingdom
  • Site Reference ID/Investigator# 0543
    London, United Kingdom
09

References and documents

Publications

  • Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V, Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF, Styles L, Flinn IW. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3. Erratum In: Lancet Oncol. 2019 Jan;20(1):e10. doi: 10.1016/S1470-2045(18)30923-9. PubMed 30522969 ↗
  • Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Novak J, Strugov V, Gill D, Gribben JG, Kwei K, Dai S, Hsu E, Dean JP, Flinn IW. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica. 2022 Sep 1;107(9):2108-2120. doi: 10.3324/haematol.2021.279012. PubMed 35021599 ↗
  • Burger JA, Robak T, Demirkan F, Bairey O, Moreno C, Simpson D, Munir T, Stevens DA, Dai S, Cheung LWK, Kwei K, Lal I, Hsu E, Kipps TJ, Tedeschi A. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leuk Lymphoma. 2022 Jun;63(6):1375-1386. doi: 10.1080/10428194.2021.2020779. Epub 2022 Jan 11. PubMed 35014928 ↗
  • Allan JN, Shanafelt T, Wiestner A, Moreno C, O'Brien SM, Li J, Krigsfeld G, Dean JP, Ahn IE. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. Br J Haematol. 2022 Feb;196(4):947-953. doi: 10.1111/bjh.17984. Epub 2021 Dec 5. PubMed 34865212 ↗
  • Greil R, Tedeschi A, Moreno C, Anz B, Larratt L, Simkovic M, Gill D, Gribben JG, Flinn IW, Wang Z, Cheung LWK, Nguyen AN, Zhou C, Styles L, Demirkan F. Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. Ann Hematol. 2021 Jul;100(7):1733-1742. doi: 10.1007/s00277-021-04536-6. Epub 2021 May 20. PubMed 34018029 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Requests for access to individual participant data from clinical studies conducted by Pharmacyclics LLC, an AbbVie Company, can be submitted through Yale Open Data Access (YODA) Project site at the following link.

Data sharing details ↗ · yoda.yale.edu

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Mar 2018, 41 months.

Results were first posted in Apr 2019, 1 year after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 41 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2014
First posted
Oct 15, 2014
StartActual
Oct 6, 2014
Primary completionActual
Mar 26, 2018
CompletionActual
Sep 3, 2019
Results first posted
Apr 16, 2019
Last update
Sep 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02264574
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Oct 15, 2014
Start date
Oct 6, 2014
Primary completion
Mar 26, 2018
Completion
Sep 3, 2019
Results posted
Apr 16, 2019
Last update
Sep 21, 2020

Study contacts

Lori Styles
study director · Pharmacyclics LLC.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibrutinib · Chlorambucil

Start the discussion